- Home
- AXSM vs PTGX Comparison
AXSM vs PTGX Comparison
Compare AXSM & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AXSM | PTGX |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 9.3B |
| IPO Year | 2015 | 2016 |
Fundamental Metrics
Financial Performance| Metric | AXSM | PTGX |
|---|---|---|
| Price | $156.47 | $139.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 14 |
| Target Price | ★ $283.63 | $178.21 |
| AVG Volume (30 Days) | 704.9K | ★ 732.3K |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.56 | N/A |
| EPS | N/A | ★ 2.35 |
| Revenue | N/A | N/A |
| Revenue This Year | $50.70 | $1,077.07 |
| Revenue Next Year | $60.69 | N/A |
| P/E Ratio | ★ N/A | $61.66 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $123.42 | $73.08 |
| 52 Week High | $260.19 | $160.81 |
Technical Indicators
Market Signals| Indicator | AXSM | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 17.69 | 44.69 |
| Support Level | $152.83 | $135.10 |
| Resistance Level | $169.11 | $142.20 |
| Average True Range (ATR) | 6.21 | 5.36 |
| MACD | -2.38 | 0.24 |
| Stochastic Oscillator | 1.41 | 29.64 |
Price Performance
Historical ComparisonAbout AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.